This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
250mg | $500 | In Stock |
500mg | $850 | In Stock |
1g | $1275 | In Stock |
Cat #: V2672 CAS #: 1346242-81-6 Purity ≥ 98%
Description: Erdafitinib (formerly known as JNJ-42756493; JNJ42756493; Balversa), a quinoxaline derivative compound and approved anticancer drug, is a novel, potent and selective, orally bioavailable, pan inhibitor of fibroblast growth factor receptor (FGFR) with potential antineoplastic activity.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 446.54 |
---|---|
Molecular Formula | C25H30N6O2 |
CAS No. | 1346242-81-6 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: 89 mg/mL (199.3 mM)r |
Water: <1 mg/mLr | |
Ethanol: 89 mg/mL (199.3 mM) | |
SMILES Code | CC(NCCN(C1=CC(OC)=CC(OC)=C1)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)C |
Synonyms | JNJ 42756493; JNJ-42756493; JNJ42756493 |
Protocol | In Vitro | Erdafitinib (JNJ-42756493) inhibits the tyrosine kinase activities of FGFR1-4 in time-resolved fluorescence assays with IC50 values of 1.2, 2.5, 3.0 and 5.7 nM, respectively. The closely related VEGFR2 kinase is less potently inhibited (30-fold less potent compared to FGFR1) by erdafitinib, with an IC50 value of 36.8 nM. Erdafitinib binds FGFR1, 3, 4, and 2 with Kd values of 0.24, 1.1, 1.4 and 2.2 nM, respectively. The Kd value for VEGFR2 is higher at 6.6 nM. Erdafitinib inhibits proliferation of FGFR1, 3, and 4 expressing cells with IC50 values of 22.1, 13.2, and 25nM, respectively. |
---|---|---|
In Vivo | In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, Erdafitinib administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.2394 mL | 11.1972 mL | 22.3944 mL | 44.7888 mL |
5mM | 0.4479 mL | 2.2394 mL | 4.4789 mL | 8.9578 mL |
10mM | 0.2239 mL | 1.1197 mL | 2.2394 mL | 4.4789 mL |
20mM | 0.1120 mL | 0.5599 mL | 1.1197 mL | 2.2394 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.